fisogatinib

fibroblast growth factor receptor 4 (FGFR4) inhibitor

Also Known As:

2-propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-; BLU-554; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide

Networked: 9 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - fisogatinib: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - fisogatinib: 9

Experts

1.	Hoeflich, Klaus P: 2 articles (12/2019 - 12/2019)
2.	Kang, Yoon-Koo: 2 articles (12/2019 - 12/2019)
3.	Kim, Richard D: 2 articles (12/2019 - 12/2019)
4.	Lengauer, Christoph: 2 articles (12/2019 - 12/2019)
5.	Schmidt-Kittler, Oleg: 2 articles (12/2019 - 12/2019)
6.	Sherwin, Cori Ann: 2 articles (12/2019 - 12/2019)
7.	Shi, Hongliang: 2 articles (12/2019 - 12/2019)
8.	Wolf, Beni B: 2 articles (12/2019 - 12/2019)
9.	Han, Ruokuo: 1 article (01/2022)
10.	Huang, Yiming: 1 article (01/2022)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 01/01/2022 - "Recent studies have shown that the FGFR4 selective inhibitor BLU-554 has clinical benefits on tumour regression in hepatocellular carcinoma patients. " 12/01/2019 - "First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma." 01/01/2023 - "A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma." 01/05/2020 - "Fisogatinib (BLU-554) is a highly selective and potent oral fibroblast growth factor receptor 4 (FGFR4) inhibitor currently in Phase I clinical trials for treatment of hepatocellular carcinoma (HCC). "
2.	Neoplasm Metastasis (Metastasis) 01/01/2023 - "Importantly, targeting FGF19 signaling with fisogatinib efficiently suppresses FGF19-induced liver metastasis in a mouse model. " 07/01/2023 - "More importantly, we found that anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib markedly inhibited FGF19-ETV4 signalling-mediated HCC metastasis. " 07/01/2023 - "Finally, anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib prominently inhibited FGF19-ETV4 signalling-induced HCC metastasis. " 01/01/2023 - "Furthermore, the combination of the FGFR4 inhibitor BLU-554 and the SRC inhibitor KX2-391 dramatically suppressed ELF4-mediated CRC metastasis. " 01/01/2021 - "Furthermore, the combination of FGFR4 inhibitor BLU-554 and CXCR2 inhibitor SB265610 dramatically decreased HOXB5-mediated HCC metastasis. "
3.	Neoplasms (Cancer) 12/01/2019 - "SIGNIFICANCE: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC. " 12/01/2019 - "Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression. "
4.	Disease Progression 12/01/2019 - "Mutations were identified in the gatekeeper and hinge-1 residues in the kinase domain of FGFR4 upon disease progression in 2 patients treated with fisogatinib, which were confirmed to mediate resistance in vitro and in vivo. "
5.	Vomiting 12/01/2019 - "Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. "

Related Drugs and Biologics

1.	Type 4 Fibroblast Growth Factor Receptor
2.	Mitogen-Activated Protein Kinases
3.	Biomarkers (Surrogate Marker)
4.	Phosphotransferases (Kinase)
5.	trametinib
6.	1- (2- bromophenyl)- 3- (7- cyano- 3H- benzotriazol- 4- yl)urea
7.	tirbanibulin